Halozyme Therapeutics (HALO) drew fresh attention after partner argenx reported encouraging data for a therapy using the ENHANZE delivery platform, along with an analyst reaffirming a positive stance on the stock.

The recent argenx data and analyst commentary come on top of steady gains in Halozyme's share price, with a 30 day share price return of 8.7% and a 1 year total shareholder return of 33.7%. This suggests momentum has been building over both shorter and longer periods.

If this kind of platform driven story interests you, it can be worth casting the net wider and checking out 40 healthcare AI stocks

With Halozyme showing double digit returns over 1 and 3 years and trading below some analyst targets, the key question is simple: is the stock still underappreciated, or are markets already pricing in much of its future growth?

Most Popular Narrative: 16.5% Undervalued

Compared with the last close at $71.60, the most followed narrative pegs Halozyme's fair value at $85.78, pointing to a valuation gap that investors are watching closely.

The company's expanding network of global partnerships and the ramp-up of recently launched subcutaneous biologics (e.g., OCREVUS ZUNOVO, Opdivo Qvantig, Tecentriq Hybreza, RYBREVANT SC) provide a robust set of new and diversified royalty streams that are still early in their adoption curve. As these launches mature and penetration increases, especially in emerging and international markets, significant sequential revenue and EBITDA growth is anticipated.

Want to see what sits behind that fair value gap? The narrative focuses on royalty growth, rising margins and a lower future earnings multiple than today. The specific projections might surprise you.

Result: Fair Value of $85.78 (UNDERVALUED)

However, this story can shift quickly if ENHANZE adoption slows or key partners like J&J, Roche or argenx face setbacks that hit royalty streams.

Another Way To Look At Valuation

Analysts see Halozyme as 16.5% undervalued on their fair value estimate. However, the current P/E of 24.3x sits well above the US Biotechs average of 16.4x and above the fair ratio of 19.4x. That gap points to valuation risk if expectations reset, so which signal do you trust more?

Next Steps

With sentiment clearly mixed, it makes sense to look at the full picture yourself and weigh both sides quickly using the 2 key rewards and 4 important warning signs.

Looking for more investment ideas?

If you stop with just one stock, you may miss opportunities that fit your style even better, so use the Simply Wall Street Screener to broaden your watchlist.

• Spot potential mispricings by scanning 47 high quality undervalued stocks that pair quality fundamentals with attractive entry points.
• Strengthen your income focus by reviewing 10 dividend fortresses that combine higher yields with a focus on resilience.
• Zero in on financial resilience with the solid balance sheet and fundamentals stocks screener (46 results) to find companies that may handle tougher periods more comfortably.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.